Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure
- First Online:
- Cite this article as:
- Chiong, J.R., Jao, G.T. & Adams, K.F. Heart Fail Rev (2010) 15: 275. doi:10.1007/s10741-009-9141-2
- 232 Downloads
The B-type natriuretic peptide (BNP) and the amino-terminal fragment of proBNP (NT-proBNP) are increased in heart failure in proportion to severity of symptoms, degree of left ventricular dysfunction, and elevation of cardiac filling pressures. These natriuretic peptides (NPs) are increasingly used for diagnostic and prognostic purposes in acute heart failure. While NP levels on admission provide independent prognostic information, serial determinations during hospitalization and at discharge better reflect adequacy of treatment and prognosis. The addition of BNP and NT-proBNP to usual clinical decision making enhances detection of high-risk patients who need aggressive follow-up and adjustment of treatment.